^
Association details:
Biomarker:No biomarker
Cancer:Cervical Cancer
Drug:Mvasi (bevacizumab-awwb) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
01/15/2018
Excerpt:
Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.
Secondary therapy:
cisplatin + paclitaxel; paclitaxel + topotecan
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of…Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan
Secondary therapy:
cisplatin + paclitaxel; paclitaxel + topotecan